TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05214066
Drug: Rabbit ATG
Normalized name: Rabbit ATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
Study: NCT02990975
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00556439
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept.
Study: NCT00981162
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00981162
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04368377
Drug: Tirofiban Injection
Normalized name: tirofiban Injection
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
Study: NCT04368377
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
Study: NCT04368377
Drug: Fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
Study: NCT03519724
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reversal of deep NMB
Study: NCT03519724
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reversal of moderate NMB
Study: NCT00099502
Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mcg administered s.c. every other day
Study: NCT00099502
Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mcg administered s.c. every other day
Study: NCT00099502
Drug: Copaxone
Normalized name: Copaxone
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg administered s.c. once daily.
Study: NCT03007420
Drug: Occipital Nerve Block (ONB) using lidocaine and dexamethosone
Normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
Study: NCT03007420
Drug: Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone
Normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
Study: NCT00238082
Drug: HFA-134A Beclomethasone DIpropionate (QVAR)
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01515579
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One single dose of 6.25 mg/mL administered subcutaneously
Study: NCT01515579
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One single dose of 6.0 mg/mL administered subcutaneously
Study: NCT01840813
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
Study: NCT01543919
Drug: PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study: NCT01543919
Drug: PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study: NCT01543919
Drug: PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study: NCT01543919
Drug: PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study: NCT01543919
Drug: PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study: NCT01054781
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1st cycle R+R-CHOP 2-8th cycle R-CHOP
Study: NCT00297739
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02128633
Drug: 5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
Study: NCT02532647
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02532647
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00299286
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle.
Study: NCT00232258
Drug: Nolpitantium besylate
Normalized name: mesylate
DrugBank: Nolpitantium chloride (DB16743)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00367081
Drug: Pyrimethamine plus Sulfadiazine plus leucoverin
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04018833
Drug: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
Normalized name: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04018833
Drug: Aflibercept 40 MG/ML Intraocular Solution [EYLEA]
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02126956
Drug: ACT-128800
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
Study: NCT00099554
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03441841
Drug: Lidocaine + Prilocaine
Normalized name: lidocaine / prilocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
Study: NCT03441841
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single topical dose of 2g lidocaine 2.5 % formulation.
Study: NCT03441841
Drug: Prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single topical dose of 2g prilocaine 2.5 % formulation.
Study: NCT00070187
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00070187
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00070187
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00070187
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00070187
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04460820
Drug: Doxorubicin Hydrochloride Liposome Injection
Normalized name: doxorubicin hydrochloride liposome Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2,IV on Day 1 of each cycle
Study: NCT02949024
Drug: IVT Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IVT aflibercept \[2 mg (50 µL)\]
Study: NCT02949024
Drug: SC CLS-TA
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[4 mg (100 µL)\]
Study: NCT01082081
Drug: Paracetamol 1000 mg
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1000 mg
Study: NCT01082081
Drug: Paracetamol 500 mg
Normalized name: Paracetamol 500 mg oral tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 500 mg
Study: NCT01163396
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01163396
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01163396
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02662426
Drug: analogous oseltamivir phosphate capsule
Normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule per time, twice per day
Study: NCT02662426
Drug: Oseltamivir phosphate capsule
Normalized name: Oseltamivir Phosphate Capsules
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule per time (75mg), twice per day
Study: NCT01202890
Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
Study: NCT02377414
Drug: Retosiban solution for Infusion
Normalized name: atosiban Injectable Solution
DrugBank: Retosiban (DB11818)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
Study: NCT01218217
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin 150 mg capsules
Study: NCT00936663
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
Study: NCT00375674
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
Study: NCT00269113
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/m2 iv monthly for 8 cycles
Study: NCT02317198
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02317198
Drug: Ticagrelor or Prasugrel
Normalized name: Ticagrelor
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00288548
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01596855
Drug: FG-4592
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIW dosing, capsule
Study: NCT01596855
Drug: Epoetin Alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIW
Study: NCT02277249
Drug: Digoxin (transvaginal administration)
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.
Study: NCT02277249
Drug: Digoxin (transabdominal administration)
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied.
Study: NCT04059081
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles.
Study: NCT02129985
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (10 ug/bid for 3 months)
Study: NCT02129985
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 850 mg/bid for 3 months
Study: NCT02075294
Drug: Adefovir dipivoxil or Entecavir
Normalized name: Adefovir Dipivoxil
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines
Study: NCT03636347
Drug: Alvelestat oral tablet - dose 1
Normalized name: Alvelestat
DrugBank: Alvelestat (DB11863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily administration
Study: NCT03636347
Drug: Alvelestat oral tablet - dose 2
Normalized name: Alvelestat
DrugBank: Alvelestat (DB11863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily administration
Study: NCT04317339
Drug: Zhigancao Tang granule
Normalized name: Zhigancao (Glycyrrhiza Glabra)
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
Study: NCT00144209
Drug: pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01480076
Drug: Fampridine
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
Study: NCT00704535
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet of 10 mg once daily
Study: NCT02503332
Drug: Pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00001437
Drug: pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02869321
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02869321
Drug: Morphine Sulfate placebo
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02155101
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.
Study: NCT00941525
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
Study: NCT01172444
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supporitory, Once Daily, Per Rectal for 6 Weeks
Study: NCT01172444
Drug: Canasa
Normalized name: Canasa
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suppository, Once Daily, Per Rectal for 6 Weeks
Study: NCT00399074
Drug: sulfadoxine pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly SP
Study: NCT02185261
Drug: Interferon Alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
Study: NCT00014274
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00014274
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00014274
Drug: vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01986894
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of 4 mg pomalidomide
Study: NCT01986894
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of 20 mg pomalidomide
Study: NCT01986894
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 400 mg moxifloxacin tablet
Study: NCT00887159
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00887159
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00887159
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01957293
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral administration, 4 mg
Study: NCT01309204
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01309204
Drug: Brinzolamide 1% ophthalmic suspension
Normalized name: Brinzolamide 1% Ophthalmic Suspension
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01309204
Drug: Brimonidine tartrate 0.2% ophthalmic solution
Normalized name: Brimonidine Tartrate 0.2% Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02786212
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01251718
Drug: donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
Study: NCT01805687
Drug: Zileuton extended release
Normalized name: zileuton Extended Release Oral Tablet
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00125814
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no